Tagged with GEN

Top 10 The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two places, followed by American firm, Celgene. Made with Visme Infographic Maker

Korea Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a private sector company. He also offers his insights into Daewoong Bio’s diversified business model and highlights the need for internationalization.…

France Frank Margain, chairman of Paris Region Entreprises, the ‘Invest in Paris Region’ promotion agency, discusses the importance of the life sciences sector for the Paris Region (Ile-de-France in French) and shares how the region is going through a key developmental period in attractivity, digitalization, and infrastructure investment.   Previously, many…

Canada As the healthcare industry continues to hype about AI’s potential to be transformative, it is important to remember that even software can harbour a certain amount of unconscious bias. Carla Smith champions transformational strategy, governance, and policy in the health sector, particularly in the areas of digital health and health IT.…

France Martin Dubuc, general manager of Biogen France, discusses the company’s strong leadership in neurosciences, its commitment to pioneering the high-risk field despite the withdrawal of many industry players, the strategy to keep MS at the core of its business while developing next-generation treatments in areas like Alzheimer’s, and the important…

China Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative commercial partnerships he has established with leading health insurance companies in China.   My medical knowledge is limited. But I…

China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…

Canada The research areas in which Canada has the potential to excel are numerous, one being the world of genomics. The stem cell itself having been discovered in Canada, Marc LePage, president and CEO of Genome Canada, identifies great potential to attract more fundamental research into that domain in the future.…

Opinion Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) in the US urges Congress to avoid restricting out-of-court drug patent settlements and to move away from anti-competitive practices that work to restrict patients access to generics and biosimilars.    Recent legislation introduced in the US Senate would…

Korea Kyoung-June Lee, CEO of JW CreaGene, lifts the lid on their novel technology of developing an immuno-oncology treatment from dendritic cells, which act as a command centre of the immune system in the body. He also assesses how this new treatment will compare to existing technologies, such as CAR-T.  …

Korea Dr BG Rhee, CEO of SCM Lifescience discusses their patented proprietary subfraction technology to extract high purity cell cultures, and the impact this will have on the efficacy, cell differentiation ability, and cost of stem cell treatments. Dr Rhee also provides his assessment of the regulatory framework for stem cells…

Spain Enrique Ordieres, president of Cinfa Group, the leading Spanish generics company, highlights the importance of diversification and internationalization in the firm’s growth strategy. He also explains the need to better value the generics market, which will, in turn, give rise to the long-term sustainability of the industry and open up…